What is the insurance difference between FDA Class II and Class III medical devices?

Class II devices are moderate-risk medical devices cleared via the 510(k) pathway - showing substantial equivalence to a predicate device. Examples: infusion pumps, diagnostic imaging instruments, networked patient monitors, connected wearables, surgical staplers, contact lenses.

Typical insurance structure: $5M-$15M products liability tower with explicit MDR liability extension covering adverse-event reporting obligations under 21 CFR Part 803. Hospital purchase contract additional-insured schedules (CG 20 10 + CG 20 37, primary/non-contributory) required for GPO supplier credentialing. Product cyber endorsement on the products policy for connected devices. Cyber tower $3M-$10M sized to PHI handling. Dedicated recall coverage at $1M-$5M.

Premium range: $40K-$200K annually for $10M-$100M revenue Class II manufacturers.

Class III devices are high-risk medical devices approved via the PMA (Pre-Market Approval) pathway - typically implantable, life-sustaining, or supporting life. Examples: pacemakers, ICDs, neurostimulators, structural heart devices, orthopedic implants, mechanical circulatory support, intraocular lenses.

Typical insurance structure: $25M-$100M+ products liability tower. Occurrence form is non-negotiable - claims surface 10-20+ years after implant date. Long-tail considerations include prior acts coverage, runoff at company exit, and tail extensions at M&A. Coordinated cyber-and-products structure for connected implantables. MDR adverse event reporting workflow documentation at underwriter audit. Recall coverage at $5M-$25M dedicated first-party limits.

Captive insurance evaluation typically begins above $250M annual revenue - the captive sits below the commercial market on working layers (products liability deductible, recall coverage) with commercial insurance providing the upper tower.

Premium range: $150K-$1M+ annually depending on subspecialty and prior incident history.

Form: Class III implantables non-negotiably need occurrence form. Class II can sometimes accept claims-made with appropriate retroactive date and tail.

Long-tail: Implant claim windows of 10-20+ years drive prior acts coverage, runoff, and tail strategy on Class III in a way Class II does not require.

Severity: Class III claim severity is materially higher - structural heart, neuromodulation, and orthopedic implant claims regularly produce mass-tort scenarios that exceed $100M aggregate.

Captive: Class III implant manufacturers reach captive structure threshold at lower revenue than Class II given the retained-risk efficiency of the captive on long-tail products lines.

Underwriting: Class III placements typically require more extensive underwriter audit - clinical trial data, post-market surveillance program documentation, MDR adverse event history, FDA inspection records, prior recall history, and design history file (DHF) summary.